Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.

Please log in to your account or sign up in order to add this asset to your watchlist.

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

OrthoPediatrics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

According to analysts' consensus price target of $62.50, OrthoPediatrics has a forecasted upside of 32.1% from its current price of $47.33.

OrthoPediatrics has only been the subject of 2 research reports in the past 90 days.

OrthoPediatrics does not currently pay a dividend.

OrthoPediatrics does not have a long track record of dividend growth.

In the past three months, OrthoPediatrics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $48,721.00 in company stock and sold $0.00 in company stock.

29.50% of the stock of OrthoPediatrics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Earnings for OrthoPediatrics are expected to grow in the coming year, from ($0.90) to ($0.72) per share.

The P/E ratio of OrthoPediatrics is -78.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

The P/E ratio of OrthoPediatrics is -78.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

OrthoPediatrics has a P/B Ratio of 4.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

Sign-up to receive the latest news and ratings for OrthoPediatrics and its competitors with MarketBeat's FREE daily newsletter.

Sign-up to receive the latest news and ratings for OrthoPediatrics and its competitors with MarketBeat's FREE daily newsletter.

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OrthoPediatrics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KIDS shares. View KIDS analyst ratings or view top-rated stocks.

4 brokerages have issued 1-year price objectives for OrthoPediatrics' shares. Their KIDS share price forecasts range from $50.00 to $77.00. On average, they expect the company's stock price to reach $62.50 in the next twelve months. This suggests a possible upside of 31.2% from the stock's current price. View analysts price targets for KIDS or view top-rated stocks among Wall Street analysts.

OrthoPediatrics' stock was trading at $59.86 at the start of the year. Since then, KIDS stock has decreased by 20.4% and is now trading at $47.64. View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022. View our KIDS earnings forecast.

OrthoPediatrics Corp. (NASDAQ:KIDS) issued its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.13. The company had revenue of $25.08 million for the quarter. OrthoPediatrics had a negative net margin of 10.88% and a negative trailing twelve-month return on equity of 7.49%.

OrthoPediatrics updated its FY 2022 earnings guidance on Tuesday, August, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $127.00 million-$130.00 million, compared to the consensus revenue estimate of $124.45 million.

15 employees have rated OrthoPediatrics Chief Executive Officer Mark Throdahl on Glassdoor.com. Mark Throdahl has an approval rating of 100% among the company's employees. This puts Mark Throdahl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other OrthoPediatrics investors own include AbbVie (ABBV), Freeport-McMoRan (FCX), Gilead Sciences (GILD), Intel (INTC), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Cisco Systems (CSCO), Walt Disney (DIS), Enterprise Products Partners (EPD) and NVIDIA (NVDA).

(KIDS) raised $52 million in an initial public offering on Thursday, October 12th 2017. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Piper and Jaffray Stifel served as the underwriters for the IPO and William Blair and BTIG were co-managers.

OrthoPediatrics trades on the NASDAQ under the ticker symbol "KIDS."

OrthoPediatrics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Brown Advisory Inc. (7.43%), Riverbridge Partners LLC (5.72%), Riverbridge Partners LLC (4.76%), DF Dent & Co. Inc. (2.35%), State Street Corp (1.87%) and Allspring Global Investments Holdings LLC (1.78%). Insiders that own company stock include (Reynolds) Marie C Infante, Bernie B Berry III, Bernie B Berry III, Daniel J Gerritzen, David R Bailey, David R Pelizzon, Fred Hite, Gregory A Odle, Harold Ruf, Jennifer N Pritzker, Joseph W Hauser, Mark C Throdahl, Mark C Throdahl, Stephen F Burns and Terry D Schlotterback. View institutional ownership trends.

Shares of KIDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.

One share of KIDS stock can currently be purchased for approximately $47.64.

OrthoPediatrics (NASDAQ:KIDS) has a market capitalization of $1.02 billion and generates $98.05 million in revenue each year. The company earns $-16,260,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

The company employs 133 workers across the globe.

OrthoPediatrics' mailing address is 2850 Frontier Drive, Warsaw IN, 46582. The official website for the company is www.orthopediatrics.com. The company can be reached via phone at (574) 268-6379, via email at tbui@theruthgroup.com, or via fax at 574-269-3692.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.